| Schedule of Reconciles Segment Direct Profit or Loss |
The following table reconciles segment direct profit or loss to the Company’s consolidated results:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
(in thousands) |
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
QTORIN CMC |
$ |
2,879 |
|
|
$ |
2,265 |
|
|
$ |
8,014 |
|
|
$ |
4,554 |
|
QTORIN rapamycin for microcystic LM |
|
480 |
|
|
|
1,103 |
|
|
|
2,880 |
|
|
|
3,492 |
|
QTORIN rapamycin for angiokeratomas |
|
843 |
|
|
|
— |
|
|
|
2,044 |
|
|
|
— |
|
QTORIN rapamycin for cutaneous VM |
|
156 |
|
|
|
827 |
|
|
|
1,313 |
|
|
|
1,527 |
|
QTORIN rapamycin for microcystic LM - Government grant income |
|
(484 |
) |
|
|
(53 |
) |
|
|
(484 |
) |
|
|
(392 |
) |
Non-program specific and unallocated research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
Salaries and stock-based compensation |
|
4,444 |
|
|
|
1,658 |
|
|
|
11,331 |
|
|
|
4,481 |
|
Consultants |
|
1,050 |
|
|
|
414 |
|
|
|
4,484 |
|
|
|
1,046 |
|
Other |
|
1,456 |
|
|
|
314 |
|
|
|
3,049 |
|
|
|
1,012 |
|
Total research and development |
$ |
10,824 |
|
|
$ |
6,528 |
|
|
$ |
32,631 |
|
|
$ |
15,720 |
|
General and administrative: |
|
|
|
|
|
|
|
|
|
|
|
Salaries and stock-based compensation |
$ |
6,614 |
|
|
$ |
2,151 |
|
|
$ |
15,044 |
|
|
$ |
5,348 |
|
Consultants |
|
3,360 |
|
|
|
587 |
|
|
|
6,053 |
|
|
|
2,497 |
|
Other |
|
1,928 |
|
|
|
911 |
|
|
|
5,258 |
|
|
|
3,733 |
|
Total general and administrative |
$ |
11,902 |
|
|
$ |
3,649 |
|
|
$ |
26,355 |
|
|
$ |
11,578 |
|
Loss from operations |
$ |
(22,726 |
) |
|
$ |
(10,177 |
) |
|
$ |
(58,986 |
) |
|
$ |
(27,298 |
) |
|